"Receptor, TIE-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A TIE receptor tyrosine kinase that is found almost exclusively on ENDOTHELIAL CELLS. It is required for both normal embryonic vascular development (NEOVASCULARIZATION, PHYSIOLOGIC) and tumor angiogenesis (NEOVASCULARIZATION, PATHOLOGIC).
| Descriptor ID |
D042787
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.925.500 D12.776.543.750.630.687.500
|
| Concept/Terms |
Receptor, TIE-2- Receptor, TIE-2
- Receptor, TIE 2
- TIE-2 Receptor
- TIE2 Tyrosine Kinase
- Tyrosine Kinase, TIE2
- TIE-2 Receptor Tyrosine Kinase
- TIE 2 Receptor Tyrosine Kinase
- Tek Receptor
- Receptor, Tek
- Tie2 Receptor
- Receptor, Tie2
- TIE-2-RTK
- Angiopoietin Receptor Tie-2
- Angiopoietin Receptor Tie 2
- Receptor Tie-2, Angiopoietin
- Tie-2, Angiopoietin Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, TIE-2".
Below are MeSH descriptors whose meaning is more specific than "Receptor, TIE-2".
This graph shows the total number of publications written about "Receptor, TIE-2" by people in this website by year, and whether "Receptor, TIE-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 4 | 0 | 4 |
| 2011 | 2 | 2 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 2 | 4 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, TIE-2" by people in Profiles.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Reconciling Flux Experiments for Quantitative Modeling of Normal and Malignant Hematopoietic Stem/Progenitor Dynamics. Stem Cell Reports. 2021 04 13; 16(4):741-753.
-
Tie-2 Cre-Mediated Deficiency of Extracellular Signal-Regulated Kinase 2 Potentiates Experimental Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension in Neonatal Mice. Int J Mol Sci. 2020 Mar 31; 21(7).
-
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 10 01; 79(19):5088-5101.
-
Endothelial Hypoxia-Inducible Factor-2a Is Required for the Maintenance of Airway Microvasculature. Circulation. 2019 01 22; 139(4):502-517.
-
Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.
-
TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Mol Cell Biol. 2017 Nov 01; 37(21).
-
TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Sci Adv. 2016 04; 2(4):e1501290.
-
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget. 2016 Mar 29; 7(13):16146-57.
-
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016 09; 18(9):1230-41.